Last reviewed · How we verify

Cefditoren Pivoxyl (CEFDITOREN PIVOXIL)

Vansen Pharma · FDA-approved approved Small molecule Quality 35/100

Cefditoren Pivoxyl (generic name: CEFDITOREN PIVOXIL) is a Cephalosporin Antibacterial Small molecule drug developed by Vansen Pharma. It is currently FDA-approved (first approved 2001) for Acute exacerbation of chronic bronchitis, Bacterial pneumonia, Haemophilus Influenzae Chronic Bronchitis.

Cefditoren Pivoxil is a cephalosporin antibacterial drug, originally developed and currently owned by Vansen Pharma. It was FDA-approved in 2001 for various respiratory infections, including acute exacerbation of chronic bronchitis and bacterial pneumonia. As an off-patent drug, it is no longer protected by active patents, but there are currently no generic manufacturers. Cefditoren Pivoxil is a small molecule that targets a range of bacterial pathogens, including Haemophilus influenzae and Staphylococcus aureus. It is used to treat infections caused by these bacteria.

At a glance

Generic nameCEFDITOREN PIVOXIL
SponsorVansen Pharma
Drug classCephalosporin Antibacterial
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved
First approval2001

Approved indications

Common side effects

Serious adverse events

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cefditoren Pivoxyl

What is Cefditoren Pivoxyl?

Cefditoren Pivoxyl (CEFDITOREN PIVOXIL) is a Cephalosporin Antibacterial drug developed by Vansen Pharma, indicated for Acute exacerbation of chronic bronchitis, Bacterial pneumonia, Haemophilus Influenzae Chronic Bronchitis.

What is Cefditoren Pivoxyl used for?

Cefditoren Pivoxyl is indicated for Acute exacerbation of chronic bronchitis, Bacterial pneumonia, Haemophilus Influenzae Chronic Bronchitis, Haemophilus Parainfluenzae Chronic Bronchitis, Haemophilus Parainfluenzae Pneumonia.

Who makes Cefditoren Pivoxyl?

Cefditoren Pivoxyl is developed and marketed by Vansen Pharma (see full Vansen Pharma pipeline at /company/vansen-pharma).

What is the generic name of Cefditoren Pivoxyl?

CEFDITOREN PIVOXIL is the generic (nonproprietary) name of Cefditoren Pivoxyl.

What drug class is Cefditoren Pivoxyl in?

Cefditoren Pivoxyl belongs to the Cephalosporin Antibacterial class. See all Cephalosporin Antibacterial drugs at /class/cephalosporin-antibacterial.

When was Cefditoren Pivoxyl approved?

Cefditoren Pivoxyl was first approved on 2001.

What development phase is Cefditoren Pivoxyl in?

Cefditoren Pivoxyl is FDA-approved (marketed).

What are the side effects of Cefditoren Pivoxyl?

Common side effects of Cefditoren Pivoxyl include Hematuria, Diarrhea, Increased urine white blood cells, Decreased hematocrit, Increased glucose, Nausea. Serious adverse events: Pseudomembranous colitis, Anaphylaxis, Stevens-Johnson syndrome, Toxic epidermal necrolysis.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing